Analysts Issue Forecasts for Envoy Medical FY2026 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – Equities researchers at HC Wainwright raised their FY2026 EPS estimates for shares of Envoy Medical in a research note issued to investors on Monday, November 9th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($2.61) per share for the year, up from their previous forecast of ($3.10). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Envoy Medical’s Q4 2026 earnings at ($0.64) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.54) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.25) EPS.

Envoy Medical (NASDAQ:COCH) last announced its earnings results on Thursday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.17. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Envoy Medical had a negative net margin of 9,026.41% and a negative return on equity of 5,250.23%.

COCH has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research note on Monday, October 19th. Lake Street Capital boosted their price objective on shares of Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Finally, Loop Capital set a $20.00 price objective on Envoy Medical in a research note on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $21.00.

Envoy Medical Trading Down 2.5%

Shares of COCH stock opened at $6.92 on Wednesday. Envoy Medical has a 12 month low of $3.63 and a 12 month high of $9.54. The stock has a market cap of $53.42 million, a P/E ratio of -1.50 and a beta of 2.03. The company has a 50 day simple moving average of $6.81 and a two-hundred day simple moving average of $6.88.

Key Stories Impacting Envoy Medical

Here are the key news stories impacting Envoy Medical this week:

• Positive Sentiment: Envoy Medical regained compliance with Nasdaq’s $1 minimum-bid-price rule after its shares closed above that threshold for 10 consecutive trading days, easing a listing-related concern. Article: Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
• Positive Sentiment: HC Wainwright reiterated its Buy rating and $18 price target. The firm also raised its FY2026 EPS estimate to a loss of $2.61 per share from a projected loss of $3.10, implying a less severe expected annual loss. HC Wainwright analyst recommendations
• Positive Sentiment: Reported short interest fell 84.4% between October 15 and October 30, to 89,915 shares. Lower short positioning may reduce potential selling pressure, though the figures are dated and another report gave a conflicting November tally. Article: Envoy Medical Shares Shorted
• Negative Sentiment: HC Wainwright cut its EPS forecasts for every quarter from Q4 2026 through Q4 2027, and lowered its FY2027 estimate to a loss of $2.25 per share from $1.80. These revisions point to greater anticipated losses over the near-term outlook and could weigh on sentiment despite the maintained Buy rating.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor. The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.